Ligelizumab
Ligelizumab (INN; development code QGE031) is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It binds to IGHE an acts as an immunomodulator.[2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IGHE |
Clinical data | |
Other names | QGE031 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6534H10000N1716O2038S44 |
Molar mass | 146612.49 g·mol−1 |
This drug was developed by Novartis Pharma AG. As of 2018, ligelizumab is undergoing Phase III trials.
Adverse drug effects
References
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.